Seelos Therapeutics, Inc.

$SEEL has been trading in a pretty tight range the last few weeks. It gapped down about a month ago after its Phase 2 trial of SLS-002. Even though the results of that trial were considered ‘promising,’ the trial had too small of a sample size and therefore did not meet its primary endpoint. Looking at the chart, if the stock can break and close a little over $0.20 it could test the $0.30 area where it initially gapped down to in September.